You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 276 No. 2, July 10, 1996 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening

J. A. Mauskopf, J. E. Paul, D. S. Wichman, A. D. White and H. H. Tilson
Glaxo Welcome Inc., Research Triangle Park, NC 27709, USA.

OBJECTIVES--To estimate the economic impact of (1) treating pregnant women who are human immunodeficiency virus (HIV)-positive with zidovudine and (2) voluntary screening programs for pregnant women for HIV infection and offering treatment with zidovudine to those found to be HIV-positive. MAIN OUTCOME MEASURES--Number of cases of pediatric HIV infection and costs of screening, zidovudine treatment, and pediatric HIV infection treatment. DESIGN--Health care costs associated with treatment of HIV-positive pregnant women and their newborns are estimated as the costs of zidovudine and its administration and the reduction in costs of treating pediatric HIV infection. The lifetime costs of pediatric HIV infection are derived from the published literature. Estimates of the reduction in maternal-to-fetal transmission rates are taken from the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group (ACTG) Protocol 076. Costs of a voluntary screening program include costs of screening tests and counseling. Sensitivity and threshold analyses are performed to determine the impact of changes in input parameter values including zidovudine treatment costs, efficacy of treatment, costs of pediatric HIV infection, prevalence of HIV infection in pregnant women, screening test sensitivity and specificity, and pregnancy termination rates on the results. RESULTS--Assuming transmission rates are reduced from 25.5% to 8.3% as found in the ACTG 076 trial, treatment costs of $104,502 for 100 HIV-positive pregnant women and their newborns are offset by the reduction of $1,701,333 associated with fewer cases of pediatric HIV infection for a net savings of $1,596,831. The sensitivity and threshold analyses show that overall cost savings from treatment of HIV-positive pregnant women and their newborns are achieved for a wide range of possible maternal treatment costs, efficacy rates, and lifetime pediatric HIV treatment costs. In the base-case analysis for the voluntary screening program, overall cost savings are seen when HIV prevalence rate among pregnant women is greater than 4.6 per 1000. However, this threshold prevalence rate is sensitive to changes In parameter value-especially pediatric HIV treatment costs, counselling costs, efficacy of treatment, and years of additional HIV treatment for the pregnant women. CONCLUSIONS--Offering zidovudine treatment to pregnant women known to be HIV-positive will decrease the number of cases of pediatric HIV infection and reduce health care costs. Voluntary screening programs for pregnant women will further decrease the number of cases of pediatric HIV infection. The effect of a screening program on health care costs varies according to HIV prevalence and the costs associated with the screening program.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
Hornberger et al.
Med Decis Making 2007;27:789-821.
ABSTRACT  

Should Older Women Have Antepartum Testing to Prevent Unexplained Stillbirth?
Fretts et al.
Obstet Gynecol 2004;104:56-64.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Interventions to Reduce Vertical HIV Transmission from Pregnant Women Who Have Not Received Prenatal Care
Mrus and Tsevat
Med Decis Making 2004;24:30-39.
ABSTRACT  

The Impact of Expected HIV Transmission Rates on the Effectiveness and Cost of Ruling Out HIV Infection in Infants
Mrus et al.
Med Decis Making 2002;22:S38-S44.
ABSTRACT  

Cost-Effectiveness of Elective Cesarean Delivery in Human Immunodeficiency Virus-Infected Women
CHEN et al.
Obstet Gynecol 2001;97:161-168.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Universal Compared With Voluntary Screening for Human Immunodeficiency Virus Among Pregnant Women in Chicago
Immergluck et al.
Pediatrics 2000;105:54e-54.
ABSTRACT | FULL TEXT  

Cost effectiveness analysis of antenatal HIV screening in United Kingdom
Ades et al.
BMJ 1999;319:1230-1234.
ABSTRACT | FULL TEXT  

State-Mandated Voluntary Newborn Human Immunodeficiency Virus Screening in a New York City Hospital
POLANECZKY et al.
Obstet Gynecol 1999;94:647-652.
ABSTRACT | FULL TEXT  

Rapid Testing and Zidovudine Treatment to Prevent Vertical Transmission of Human Immunodeficiency Virus in Unregistered Parturients: A Cost-Effectiveness Analysis
STRINGER and ROUSE
Obstet Gynecol 1999;94:34-40.
ABSTRACT | FULL TEXT  

HIV Screening and Treatment of Pregnant Women and Their Newborns: A Simulation-Based Analysis
Anderson and Anderson
SIMULATION 1998;71:276-284.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.